(R)-n-甲基-1-[4-(三氟甲基)苯基]乙胺 | 672906-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-n-甲基-1-[4-(三氟甲基)苯基]乙胺
• 英文名称: (R)-N-methyl-1-(4-(trifluoromethyl)phenyl)ethyl-1-amine
• 英文别名: (R)-N-methyl-1-(4-(trifluoromethyl)phenyl)ethan-1-amine；(R)-1-(4-trifluoromethylphenyl)ethylamine N-monomethyl；(R)-N-methyl-1-[4-(trifluoromethyl)phenyl]ethylamine；(1R)-N-methyl-1-[4-(trifluoromethyl)phenyl]ethanamine
• CAS: 672906-72-8
• 化学式: C₁₀H₁₂F₃N
• 分子量: 203.207
• InChiKey: HJCYBPVJJPKIFJ-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  (R)-n-甲基-1-[4-(三氟甲基)苯基]乙胺 、 1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-ethoxycarbonylmethyl-1H-pyrazole-3-carboxylic acid 在 N,N-二甲基甲酰胺 草酰氯 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 (1-(2-Chloro-phenyl)-5-(4-chloro-phenyl)-3-{methyl-[(R)-1-(4-trifluoromethyl-phenyl)-ethyl]-carbamoyl}-1H-pyrazol-4-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  WO2008/75012

  摘要：

  公开号：
• 作为产物：
  描述：

  (R)-N-(tert-butoxycarbonyl)-N-methyl-1-(4-trifluoromethyl)phenylethylamine 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以55.98 %的产率得到(R)-n-甲基-1-[4-(三氟甲基)苯基]乙胺
  参考文献：
  名称：

  [EN] NOVEL PRMT5 INHIBITOR AND USE THEREOF
  [FR] NOUVEL INHIBITEUR DE PRMT5 ET SON UTILISATION
  [ZH] 新型PRMT5抑制剂及其应用

  摘要：

  本发明描述了具有蛋白精氨酸甲基转移酶5抑制活性的新型分子，以及该化合物的合成和使用方法。具体地，本发明描述了式(I)化合物或其药学上可接受的盐、水合物或溶剂合物，以及该化合物的合成和使用方法。

  公开号：

  WO2024032572A1

文献信息

• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CANNABINOÏDES
  申请人：7TM PHARMA AS

  公开号：WO2009074782A1

  公开（公告）日：2009-06-18

  Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein:X is a bond, or a divalent radical selected from -C(R10)(R11)-*, -C(R10)(R11)-O-*, -C(R10)(R11)CH2-*, -C(R10)(R11)CH2-O-*, -CH2C(R10)(R11)-*, -CH2C(R10)(R11) -O-*. and -CH2-O-C(R10)(R11)-*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is a carboxyl isostere radical selected from the group specified; R3 is hydrogen, (C1-C)aIkyI or (C1C3)fluoroalkyl; R4 is a radical of formula -(AIk1)P-(Q1)r (L)s -Q2 wherein p, r, s, AIk1, L, Q1 and Q2 are as specified; or R3 and R4 taken together with the nitrogen to which they are attached form a cyclic amino ring of 4 to 7 ring atoms which is optionally substituted by a radical of formula -(L)s-Q2 wherein s, L and Q2 are as defined above, or by an optional substituent selected from hydroxy, methoxy, -NH2-, or mono- or di-(C1C3)alkylamino; R5, R6, R7 and R8 are each independently selected from hydrogen -F, -Cl, -Br, -CN, (C1-C3)alkyl, (C1C3)fluoroalkyl, cyclopropyl, and -OR9; R10 is hydrogen, (C1C3)alkyl, hydroxyl or NH2, and R11 is hydrogen or (C1-C3)alkyl; or R10 and R11 taken together with the carbon atom to which they are attached form a (C3-C5)cycloalkyl ring.

  式(I)的化合物是大麻素受体CB1的调节剂，可用于治疗肥胖：式(I)。其中：X是一个键，或者从-C(R10)(R11)-*、-C(R10)(R11)-O-*、-C(R10)(R11)CH2-*、-C(R10)(R11)CH2-O-*、-CH2C(R10)(R11)-*、-CH2C(R10)(R11) -O-*中选择的二价基团。和-CH2-O-C(R10)(R11)-*，其中星号表示连接到吡唑环的键；Z是从指定组中选择的羧基异构基团；R3是氢、(C1-C)aIkyI或(C1C3)氟烷基；R4是式-(AIk1)P-(Q1)r(L)s-Q2的基团，其中p、r、s、AIk1、L、Q1和Q2如指定；或者R3和R4与它们连接的氮一起形成一个含有4至7个环原子的环氨基环，该环可选地被式-(L)s-Q2中的基团或上述定义的s、L和Q2定义的基团取代，或者通过一个可选的取代基团选择自羟基、甲氧基、-NH2-或单或双-(C1C3)烷基胺；R5、R6、R7和R8分别独立地选择自氢、-F、-Cl、-Br、-CN、(C1-C3)烷基、(C1C3)氟烷基、环丙基和-OR9；R10是氢、(C1C3)烷基、羟基或NH2，R11是氢或(C1-C3)烷基；或者R10和R11与它们连接的碳原子一起形成一个(C3-C5)环烷基环。
• CB1 RECEPTOR MODULATORS
  申请人：Cooper Martin

  公开号：US20100010061A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A 1 is hydrogen, —COOH, or tetrazolyl, and A 2 is hydrogen, —COOH, or tetrazolyl, provided that one of A 1 and A 2 is either —COOH or tetrazolyl; p is 0 or 1 and A 3 is phenyl or cycloalkyl, either of which is optionally substituted with R 4 and/or R 5 ; q is 0 or 1; R 3 is hydrogen, C 1 -C 4 alkyl, cycloalkyl, —CF 3 , or —OR 9 ; R 4 and R 5 independently —R 9 , —CN, —F, —Cl, —Br, —OR 9 , —NR 7 R 8 , —NR 7 COR 6 , —NR 7 SO 2 R 6 , —COR 6 , —SR 9 , —SOR 9 , or —SO 2 R 6 ; R 6 is C 1 -C 4 alkyl, cycloalkyl, —CF 3 or —NR 7 R 8 ; R 7 and R 8 are independently hydrogen, C 1 -C 4 alkyl, —CF 3 , or cycloalkyl; R 9 is hydrogen, C 1 -C 4 alkyl, cycloalkyl, fully or partially fluorinated C 1 -C 4 alkyl; R 1 is (i) a bond, or (ii) —(CH 2 ) a B 1 (CH 2 ) b — wherein a and b are independently 0, 1, 2 or 3 provided that a+b is 1, 2 or 3; or (iii) —C(R 10 )(R 11 )—*, —C(R 10 )(R 11 )—O—*, —C(R 10 )(R 11 )CH 2 —*, —C(R 10 )(R 11 )CH 2 —O—*, —CH 2 C(R 10 )(R 11 )—*, —CH 2 C(R 10 )(R 11 )—O—*, —CH 2 —O—C(R 10 )(R 11 )—* or —C(R 10 )(R 11 )—O—CH 2 —*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; R 2 is a divalent radical of formula -Q 1 -A 4 -[Q 2 ] w - wherein Q1, A4 Q2 and w are as defined in the specification; and R 10 is hydrogen and R 11 is (C 1 -C 3 )alkyl or —OH; or R 10 and R 11 are both (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring.

  式(I)的化合物抑制CB1受体的正常信号活动，因此在治疗由CB1受体信号活动介导的疾病或病症方面有用，例如治疗肥胖和超重，预防体重增加，直接或间接与肥胖和超重相关的疾病和病症的治疗：其中A1是氢，-COOH或四唑基，A2是氢，-COOH或四唑基，但A1和A2中的一个是-COOH或四唑基；p为0或1，A3是苯基或环烷基，其中任一种都可以被R4和/或R5取代；q为0或1；R3是氢，C1-C4烷基，环烷基，-CF3或-OR9；R4和R5独立地是-R9，-CN，-F，-Cl，-Br，-OR9，-NR7R8，-NR7COR6，-NR7SO2R6，-COR6，-SR9，-SOR9或-SO2R6；R6是C1-C4烷基，环烷基，-CF3或-NR7R8；R7和R8独立地是氢，C1-C4烷基，-CF3或环烷基；R9是氢，C1-C4烷基，环烷基，完全或部分氟化的C1-C4烷基；R1是（i）键，或（ii）-（CH2）aB1（CH2）b-，其中a和b独立地为0、1、2或3，但a+b为1、2或3；或（iii）-C（R10）（R11）- *，-C（R10）（R11）-O- *，-C（R10）（R11）CH2- *，-C（R10）（R11）CH2-O- *，-CH2C（R10）（R11）- *，-CH2C（R10）（R11）-O- *，-CH2-O-C（R10）（R11）- *或-C（R10）（R11）-O-CH2- *，其中星号表示连接到吡唑环的键；R2是式-Q1-A4-[Q2]w-的二价基团，其中Q1，A4，Q2和w在规范中定义；R10是氢，R11是（C1-C3）烷基或-OH；或R10和R11都是（C1-C3）烷基；或R10和R11与它们所连接的碳原子一起形成（C3-C5）环烷基环。
• Cannabinoid Receptor Modulators
  申请人：Receveur Jean Marie

  公开号：US20100292273A1

  公开（公告）日：2010-11-18

  Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein: X is a bond, or a divalent radical selected from —C(R 10 )(R 11 )—*, —C(R 10 )(R 11 )—O—*, —C(R 10 )(R 11 )CH 2 —*, —C(R 10 )(R 11 )CH 2 —O—*, —CH 2 C(R 10 )(R 11 )—*, —CH 2 C(R 10 )(R 11 )—O—*. and —CH 2 —O—C(R 10 )(R 11 )—*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is a carboxyl isostere radical selected from the group specified; R 3 is hydrogen, (C 1 -C)alkyl or (C 1 C 3 )fluoroalkyl; R 4 is a radical of formula -(Alk 1 ) p -(Q 1 ) r (L) s -Q 2 wherein p, r, s, Alk 1 , L, Q 1 and Q 2 are as specified; or R 3 and R 4 taken together with the nitrogen to which they are attached form a cyclic amino ring of 4 to 7 ring atoms which is optionally substituted by a radical of formula -(L) s -Q 2 wherein s, L and Q 2 are as defined above, or by an optional substituent selected from hydroxy, methoxy, —NH 2 —, or mono- or di-(C 1 C 3 )alkylamino; R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen —F, —Cl, —Br, —CN, (C 1 -C 3 )alkyl, (C 1 C 3 )fluoroalkyl, cyclopropyl, and —OR 9 ; R 10 is hydrogen, (C 1 C 3 )alkyl, hydroxyl or NH 2 , and R 11 is hydrogen or (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring.

  式(I)的化合物是大麻素受体CB1的调节剂，可用于肥胖症的治疗：式(I)。其中：X是键或二价基团，选择自-C(R10)(R11)-*，-C(R10)(R11)-O- *，-C(R10)(R11)CH2- *，-C(R10)(R11)CH2-O- *，-CH2C(R10)(R11)-*，-CH2C(R10)(R11)-O- *和-CH2-O-C(R10)(R11)-*，其中由星号表示的键连接到吡唑环；Z是羧基异构基团，选择自指定的群组；R3是氢，(C1-C)烷基或(C1C3)氟烷基；R4是式-(Alk1)p-(Q1)r(L)s-Q2的基团，其中p，r，s，Alk1，L，Q1和Q2如所述；或R3和R4与它们所连接的氮一起形成4到7个环原子的环状氨基环，可选地被式-(L)s-Q2的基团或由上述定义的氢氧化物，甲氧基，-NH2-或单或双-(C1C3)烷基氨基取代；R5、R6、R7和R8各自独立地选择自氢，-F，-Cl，-Br，-CN，(C1-C3)烷基，(C1C3)氟烷基，环丙基和-OR9；R10是氢，(C1C3)烷基，羟基或NH2，R11是氢或(C1-C3)烷基；或R10和R11与它们所连接的碳原子一起形成(C3-C5)环烷基环。
• CANNABINOID RECEPTOR MODULATORS
  申请人：7TM Pharma A/S

  公开号：EP2231615A1

  公开（公告）日：2010-09-29
• US8124634B2
  申请人：——

  公开号：US8124634B2

  公开（公告）日：2012-02-28